Leadership Overview
Eisai Global has 10 executives leading key functions including strategy, finance, and regional operations.
Driven by a human health care approach, Eisai Global develops and produces medicines, extending beyond traditional pharmaceutical services to foster patient-centered healthcare solutions across global markets.
Driven by a human health care approach, Eisai Global develops and produces medicines, extending beyond traditional pharmaceutical services to foster patient-centered healthcare solutions across global markets.
Leadership Roles at Eisai Global
Tatsuyuki Yasuno - Chairman & Chief Executive Officer & Eisai Inc Region President (Americas)
Tatsuyuki Yasuno, the Chairman & Chief Executive Officer & Eisai Inc Region President (Americas) at Eisai Global, directs the overarching strategy and operational execution across the Americas region. This leadership role involves guiding the company's pharmaceutical development and manufacturing initiatives, ensuring alignment with the human health care approach. Yasuno oversees the integration of business-to-business and business-to-consumer operations within North America, driving market presence and patient-centered solutions. The Chairman & Chief Executive Officer & Eisai Inc Region President (Americas) ensures robust research and development efforts translate into tangible healthcare advancements. By focusing on critical therapeutic areas, Tatsuyuki Yasuno strengthens Eisai's commitment to improving patient outcomes and expanding access to vital medicines throughout the Americas.
Haruo Naito - Director, Representative Corporate Officer and Chief Executive Officer
Haruo Naito, the Director, Representative Corporate Officer and Chief Executive Officer at Eisai Global, spearheads the company's global strategic direction and corporate governance. This executive position involves shaping the long-term vision for pharmaceutical innovation and patient care, reinforcing Eisai's commitment to its human health care philosophy. Naito directs the integration of research and development activities across all operational regions, ensuring a unified approach to addressing unmet medical needs. The Director, Representative Corporate Officer and Chief Executive Officer fosters cross-functional collaboration to enhance the development and production of medicines. By championing patient-centered healthcare solutions, Haruo Naito drives Eisai's mission to make a significant impact on global health and well-being.
Brian Harraka - Vice President & Chief Financial Officer
Brian Harraka, the Vice President & Chief Financial Officer at Eisai Global, manages the company's financial health and strategic fiscal planning. This executive function involves overseeing all financial operations, including budgeting, forecasting, and investment strategies, to support Eisai's global expansion and research initiatives. Harraka ensures robust financial controls are in place, safeguarding assets and optimizing resource allocation across business-to-business and business-to-consumer segments. The Vice President & Chief Financial Officer plays a pivotal role in evaluating new market opportunities and managing financial risks associated with pharmaceutical development. By providing critical financial insights, Brian Harraka enables Eisai Global to sustain its commitment to patient-centered healthcare solutions and long-term growth.
Hiroyuki Murayama - President (Japan) & Promotion Department Manager, Product Strategy
Hiroyuki Murayama, the President (Japan) & Promotion Department Manager, Product Strategy at Eisai Global, leads the strategic development and market introduction of pharmaceutical products within the crucial Japanese market. This dual role involves overseeing both the operational leadership in Japan and the strategic planning for product promotion and market penetration. Murayama directs initiatives to align product strategies with patient needs, ensuring that Eisai's medicines effectively reach those requiring them. The President (Japan) & Promotion Department Manager, Product Strategy collaborates closely with research and development teams to translate scientific advancements into viable commercial offerings. By focusing on effective product promotion and strategic market positioning, Hiroyuki Murayama strengthens Eisai's presence and impact in Japan.
Toshimitsu Uenaka - President, Epochal Precision Anti-Cancer Therapeutics
Toshimitsu Uenaka, the President, Epochal Precision Anti-Cancer Therapeutics at Eisai Global, drives the strategic direction and execution of innovative oncology treatments. This specialized leadership role focuses on advancing precision medicine within the field of cancer therapy, aligning research and development efforts with patient outcomes. Uenaka oversees the integration of cutting-edge technologies and scientific discoveries to create novel anti-cancer therapeutics. The President, Epochal Precision Anti-Cancer Therapeutics ensures that Eisai's pipeline in oncology reflects a deep commitment to addressing the complex needs of cancer patients. By championing advancements in this critical therapeutic area, Toshimitsu Uenaka reinforces Eisai's dedication to improving lives through groundbreaking pharmaceutical solutions.
Yanhui Feng - President & General Manager (Eci)
Yanhui Feng, the President & General Manager (Eci) at Eisai Global, directs the strategic operations and business development for the Eci division. This leadership position involves overseeing the comprehensive management of Eisai's activities within this specific entity, ensuring alignment with the company's broader mission and human health care philosophy. Feng drives initiatives to enhance product development, manufacturing efficiency, and market reach for the Eci segment. The President & General Manager (Eci) fosters collaboration across departments to achieve operational excellence and expand Eisai's impact. By focusing on strategic growth and operational effectiveness, Yanhui Feng contributes significantly to Eisai Global's overall success and its commitment to patient-centered healthcare solutions.
Michael Montaigne - President, Eisai Machinery (USA)
Michael Montaigne, the President, Eisai Machinery (USA) at Eisai Global, leads the strategic direction and operational management of the machinery division within the United States. This executive role involves overseeing the development, production, and distribution of specialized machinery crucial for pharmaceutical manufacturing and related industries. Montaigne ensures that Eisai Machinery (USA) adheres to the highest standards of quality and innovation, supporting the broader company's commitment to advancing healthcare solutions. The President, Eisai Machinery (USA) drives operational efficiency and technological advancement within the division. By focusing on robust machinery solutions, Michael Montaigne contributes to the seamless execution of Eisai's pharmaceutical development and production processes in the US market.
Kazuhiko Tamura - Vice President and President, Eisai Demand Chain Systems
Kazuhiko Tamura, the Vice President and President, Eisai Demand Chain Systems at Eisai Global, oversees the strategic management and optimization of the company's supply chain and distribution networks. This critical function ensures the efficient and reliable delivery of Eisai's pharmaceutical products to markets worldwide, supporting the human health care approach. Tamura drives initiatives to enhance logistical efficiency, inventory management, and overall supply chain resilience across global operations. The Vice President and President, Eisai Demand Chain Systems collaborates with various departments to ensure seamless product flow from manufacturing to patient access. By strengthening the demand chain systems, Kazuhiko Tamura plays a vital role in Eisai's commitment to providing timely and accessible healthcare solutions.
Shawn Gallagher - President, Partnership Management Core Functional Unit
Shawn Gallagher, the President, Partnership Management Core Functional Unit at Eisai Global, directs the strategic development and execution of key collaborations and alliances. This leadership role focuses on identifying, nurturing, and managing partnerships that advance Eisai's research, development, and commercialization objectives. Gallagher oversees the cultivation of relationships with external organizations, ensuring mutual benefit and alignment with the company's human health care philosophy. The President, Partnership Management Core Functional Unit plays a crucial part in expanding Eisai's reach and impact through strategic external engagement. By fostering strong partnerships, Shawn Gallagher contributes to Eisai Global's mission of delivering innovative patient-centered healthcare solutions.
Makoto Hoketsu - Vice President & Chief Information Officer
Makoto Hoketsu, the Vice President & Chief Information Officer at Eisai Global, architects the company's technological infrastructure and digital strategy. This critical role ensures that information systems effectively support Eisai's global pharmaceutical operations and research endeavors. Hoketsu oversees the implementation of advanced IT solutions that enhance data management, streamline development processes, and bolster cybersecurity measures across all regions. The Vice President & Chief Information Officer drives innovation in digital health platforms, aligning technology with the company's human health care approach. By optimizing data utilization and ensuring system reliability, Makoto Hoketsu empowers Eisai's teams to accelerate the discovery and delivery of patient-centered medicines worldwide.
Explore Leadership Teams in Manufacturing
Founded in 1781, Takeda Pharmaceutical Company engages in the research, development, manufacturing, and marketing of pharmaceutical products, over-the-counter medicines and quasi-drug consumer products, and other healthcare products. It offers pharmaceutical products in the areas of gastroenterology; oncology; neuroscience; and rare diseases, such as rare metabolic and hematology, and heredity angioedema, as well as plasma-derived therapies and vaccines. The company is headquartered in Tokyo, Japan
Company Leadership RP
EW
JH
Merz North America Inc is a company that operates in the Pharmaceuticals industry. It employs 1000to4999 people and has 500Mto1G of revenue. The company is headquartered in Raleigh, North Carolina.
Company Leadership AS
PU
KK
Founded in 1974, Apotex is a proud Canadian, global pharmaceutical company that produces high-quality, affordable medicines (both generic and innovative pharmaceuticals) for patients around the world.
Company Leadership
TM
CV
MG
ImmunityBio is a vertically-integrated biotechnology company developing next-generation therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. The Companys range of immunotherapy and cell therapy platforms, alone and together, act to drive and sustain an immune response with the goal of creating durable and safe protection against disease. Designated an FDA Breakthrough Therapy, ANKTIVA is the first FDA-approved immunotherapy for non-muscle invasive bladder cancer CIS that activates natural killer cells, T cells, and memory T cells for a long-duration response. The Company is applying its science and platforms to treating cancers, including the development of potential cancer vaccines, as well as developing immunotherapies and cell therapies that we believe sharply reduce or eliminate the need for standard high-dose chemotherapy. These platforms and their associated product candidates are designed to be more effective, accessible, and easily administered than current standards of care in oncology and infectious diseases.
Company Leadership FJ
Frequently Asked Questions Regarding Eisai Global Top Executives and Leadership Team
